Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully h ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Dupilumab is undergoing Priority Review by the FDA as an add-on maintenance therapy for adults with uncontrolled COPD and type 2 inflammation, with a target action date of June 27, 2024, according ...

In a phase 3, double-blind, randomized trial, we assigned patients with COPD who had a blood eosinophil count of 300 cells per microliter or higher to receive subcutaneous dupilumab (300 mg) or ...

Dupilumab Improves Quality of Life for COPD Patients — There remains an unmet need for effective COPD therapies, expert says by Katherine Kahn , Staff Writer, MedPage Today October 10, 2024 ...

Dupilumab Reduces COPD Exacerbations — Lung function and symptoms also bettered with biologic in patients with type 2 Inflammation by Salynn Boyles, Contributing Writer May 22, 2023 ...

MONDAY, Oct. 7, 2024 (HealthDay News) -- Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according ...

Findings from BOREAS and NOTUS showed dupilumab significantly reduced moderate to severe acute COPD exacerbations vs placebo. The Food and Drug Administration (FDA) has accepted for Priority ...

Surya Bhatt, M.D., MSPH Surya Bhatt, M.D., MSPH, professor of medicine in the Division of Pulmonary, Allergy, & Critical Care Medicine, is the latest winner of the Heersink School of Medicine's ...

B OSTON -- Patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation had greater improvements in quality of life with dupilumab (Dupixent) versus placebo, according to a ...